Introduction The optimal duration of osteoporosis treatment is controversial. As opposed to
bisphosphonates, denosumab does not incorporate into bone matrix and bone turnover is …

The fully human monoclonal antibody denosumab was approved for treatment of
osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces …

Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Background Long-term safety and efficacy of osteoporosis treatment are important because
of the chronic nature of the disease. We aimed to assess the long-term safety and efficacy of …

Denosumab reduces bone resorption and vertebral and nonvertebral fracture risk.
Denosumab discontinuation increases bone turnover markers 3 months after a scheduled …

Abstract Introduction In 2008, the UK National Osteoporosis Guideline Group (NOGG)
produced a guideline on the prevention and treatment of osteoporosis, with an update in …

Osteoporosis is a skeletal disorder that causes impairment of bone structure and strength,
leading to a progressively increased risk of fragility fractures. The global prevalence of …

Denosumab is a potent antiresorptive agent that substantially increases bone mineral
density and reduces fracture rates at all skeletal sites for as long as it is administered …

We aimed to study the clinical and imaging characteristics of patients sustaining vertebral
fractures after denosumab discontinuation. For this purpose, we conducted a computerized …

Since the receptor activator of nuclear factor-kappa B ligand (RANKL), its cognate receptor
activator of nuclear factor-kappa B (RANK), and the decoy receptor osteoprotegerin (OPG) …